Navigation Links
US FDA Admits Risks of Mercury Dental Fillings, Settles Lawsuit
Date:6/5/2008

Statement of Michael Bender, Plaintiff

WASHINGTON, June 5 /PRNewswire-USNewswire/ -- "After 32 years of delay, the Food and Drug Administration has finally agreed to comply with the law and set a date to classify mercury amalgam as a substance that poses a health risk to pregnant women and unborn babies, and children. This about-face resulted from settling, earlier this week, our lawsuit, Moms Against Mercury et al. v. Von Eschenbach, Commissioner, et al. The FDA must now finish classification within one year of the close of the public comment period on its amalgam policy, that is, by July 28, 2009. The FDA also agreed to and, with uncharacteristic speed, has already changed its website on mercury amalgam -- dramatically.

Gone are all of FDA's claims that no science exists that amalgam is unsafe, or that other countries have acted for environmental reasons only, or that the 2006 FDA advisory panel affirmed amalgam's safety, all of which are untrue. Instead, the FDA has moved to a more neutral course, while still recognizing the serious health risks posed by amalgam in particular for children and unborn children, for pregnant women, and for those with mercury immuno-sensitivity.

The Updated June 3, 2008 FDA website (see: http://www.fda.gov/cdrh/consumer/amalgams.html) now states, for example:

"Dental amalgams contain mercury, which may have neurotoxic effects on the nervous systems of developing children and fetus."

"Pregnant women and persons who may have a health condition that makes them more sensitive to mercury exposure, including individuals with existing high levels of mercury bioburden, should not avoid seeking dental care, but should discuss options with their health practitioner."

In September 2006, an advisory panel to the FDA reviewed FDA's research and heard presentations from the public about the benefits and risks of mercury and amalgam. The joint committee concluded with personal recommendations by the members. These include that FDA should:

Consider informed consent for patients receiving amalgam

Consider labeling changes restricting its use in pregnant woman and children

Consider the relevancy of the "precautionary principle"

You can read the summary of the FDA advisory panel meeting at: http://www.fda.gov/cdrh/meetings/090606-summary.html

The FDA website now also states that "Some other countries follow a 'precautionary principle' and avoid the use of dental amalgam in pregnant women. The FDA provides links to advice about dental amalgams from regulatory agencies in other countries:

Canada: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/1996/1996_63_e.html

France: http://afssaps.sante.fr/ang/pdf/amalgam.pdf

Sweden: http://www.kemi.se/templates/Page.aspx?id=5233 "

The plaintiffs included a team of four nonprofit groups, two public officials, three dental professionals, and two consumer victims: Moms Against Mercury (Amy Carson and Angela Medlin), Connecticut Coalition for Environmental Justice (Dr. Mark Mitchell), Oregonians for Life (Mary Starrett), mercury expert Michael Bender (as a of the Vermont Advisory Committee on Mercury Pollution), Arizona Senator Karen Johnson, Dr. Andy Landerman, Dr. Corrie Crowe, dental assistant Karen Palmer, consumer advocates Linda Brocato and Anita Vazquez Tibau, and Consumers for Dental Choice.

For More Information: http://www.mercurypolicy.org


'/>"/>
SOURCE Mercury Policy Project
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sutter Admits: Closing St. Lukes Likely to Reduce Charity Care
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Informational handout key to giving parents a better understanding of CT radiation risks
4. Stanford study highlights cost-effective method of lowering heart disease risks
5. Hispanic Teens Take More Skin Cancer Risks
6. Smoking increases risks for head and neck cancers for men and women
7. Case Management Cost-Effective Way to Cut Heart Risks
8. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
9. Diabetes Drug Avandia Boosts Heart Risks: Study
10. Federal research plan to determine nanotech risks fails to deliver
11. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology: